GCG and type 2 diabetes mellitus: Since available data relating to the glycemic and nonglycemic CVD risk factor response to GLP-1 RA therapy have come largely from people with type 2 diabetes without CVD or at low CVD risk who have participated in Phase III studies, we examined EQW-related changes in cardiometabolic risk factors in participants in the large-scale Phase IV Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [11], with particular reference to those who were Asian.